Single dose PK study on Patients [Design Issues]

posted by Pharma_88 – India, 2024-05-17 12:06 (360 d 23:19 ago) – Posting: # 23998
Views: 3,348

Dear Ohlbe,

Thank you for responding. Drug is Olaparib and OGD recommends Two-way crossover Steady State PK study. One of our client wish to conduct single dose BE study as a conventional design without interrupting ongoing treatment of patient. Now whether its a feasible by taking appropriate measures of clinical safety?

Regards,
Pharma_88


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Ohlbe]

Regards,
Pharma_88

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,668 registered users;
88 visitors (0 registered, 88 guests [including 50 identified bots]).
Forum time: 11:26 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5